Simvastatin prevents alveolar bone loss in an experimental rat model of periodontitis after ovariectomy

Journal of Translational Medicine

Er-yi Lu²  An Qin¹  Xu-qiang Liu¹  Zan-jing Zhai¹  Xi Zhang²  Hui Chen²  Xin-chen Xu² 

[1] Department of Orthopaedic, Shanghai Ninth People¿s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Orthopaedic Implant, 639 Zhizaoju Road, Shanghai 200011, China;Department of Prosthodontics, Shanghai Ninth People¿s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Key Laboratory of Stomatology, 639 Zhizaoju Road, Shanghai 200011, China

关键词: Maxillary;    Osteoporosis;    Periodontitis;    Alveolar bone loss;    Simvastatin;   

Others  :  1147834
DOI  :  10.1186/s12967-014-0284-0

 received in 2014-07-15, accepted in 2014-09-25,  发布年份 2014

【 摘 要 】

Background

Periodontitis is an inflammatory disease characterized by the loss of connective tissue and alveolar bone. There is an increasing evidence that periodontitis is associated with a number of chronic disease, including osteoporosis. Periodontitis and osteoporosis are both bone destructive diseases and of high prevalence in adult population. Osteoporosis could increase some inflammatory factors that also participate in the progression of periodontitis, so as to facilitate the alveolar bone resorption. Simvastatin, specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme reductase, is of pleiotropic effects including anti-catabolic and anabolic effect on bone metabolism. This study aimed to explore the local and systemic effect of simvastatin on maxillary in rats with both osteoporosis and periodontitis.

Methods

Thirty-six 4-month-old female Sprague Dawley rats were randomly assigned to six groups: sham group, ligature group, ovariectomized (OVX)?+?ligature group, local simvastatin administration to OVX?+?ligature rats (local simvastatin group), oral simvastatin administration to OVX?+?ligature rats (oral simvastatin group), local and oral simvastatin administration to OVX?+?ligature rats (L&O simvastatin group). One month after OVX, ligatures were placed on the maxillary first (M1) and second molars (M2) for 4 weeks on all rats except those in the sham group, followed by simvastatin treatment for 2 months. The maxillae, serum, and femurs were collected for further examination including micro-computed (micro-CT) tomography, hematoxylin and eosin (H&E) staining, tartrate-resistant acid phosphatase (TRAP) staining, enzyme-linked immunosorbent assays (ELISA), and the three-point bending test.

Results

Local simvastatin administration increased alveolar crest height and prevented local alveolar bone loss without alteration of systemic bone loss. Oral administration prevented local and systemic bone loss with no effect on alveolar crest height.

Conclusions

Our results indicate that simvastatin has the potential of promoting bone formation and reducing alveolar bone loss in maxillary following ovariectomy (OVX) and ligature placement in rats.

【 授权许可】

   
2014 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pihlstrom BL, Michalowicz BS, Johnson NW: Periodontal diseases. Lancet 2005, 366:1809-1820.
• [2]Wactawski-Wende J: Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 2001, 6:197-208.
• [3]?: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.World Health Organ Tech Rep Ser 1994, 843:1¿129.
• [4]Passos JS, Vianna MI, Gomes-Filho IS, Cruz SS, Barreto ML, Adan L, Rosing CK, Cerqueira EM, Trindade SC, Coelho JM: Osteoporosis/osteopenia as an independent factor associated with periodontitis in postmenopausal women: a case¿control study. Osteoporos Int 2013, 24:1275-1283.
• [5]Guiglia R, Di Fede O, Lo Russo L, Sprini D, Rini G-B, Campisi G: Osteoporosis, jawbones and periodontal disease. Med Oral Patol Oral Cir Bucal 2013, 18:e93-99.
• [6]Brennan-Calanan RM, Genco RJ, Wilding GE, Hovey KM, Trevisan M, Wactawski-Wende J: Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res 2008, 87:323-327.
• [7]Loo WTY, Fan C-b, Bai L-j, Yue Y, Dou Y-d, Wang M, Liang H, Cheung MNB, Chow LWC, Li J-l, Tian Y, Qing L: Gene polymorphism and protein of human pro- and anti-inflammatory cytokines in Chinese healthy subjects and chronic periodontitis patients. J Transl Med 2012, 10(Suppl 1):S8. BioMed Central Full Text
• [8]Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
• [9]Buhaescu I, Izzedine H: Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007, 40:575-584.
• [10]Yoshida T, Asanuma M, Grossmann L, Fuse M, Shibata T, Yonekawa T, Tanaka T, Ueno K, Yasuda T, Saito Y, Tatsuno I: Geranylgeranyl-pyrophosphate (GGPP) synthase is down-regulated during differentiation of osteoblastic cell line MC3T3-E1. FEBS Lett 2006, 580:5203-5207.
• [11]Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15:1467-1476.
• [12]Jia Y-J, Xu R-X, Sun J, Tang Y, Li J-J: Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med 2014, 12:103. BioMed Central Full Text
• [13]Mundy GR: Statins and their potential for osteoporosis. Bone 2001, 29:495-497.
• [14]Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44.
• [15]Sadowitz B, Maier KG, Gahtan V: Basic science review: Statin therapy¿Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010, 44:241-251.
• [16]Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
• [17]Moon HJ, Kim SE, Yun YP, Hwang YS, Bang JB, Park JH, Kwon IK: Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med 2011, 43:605-612.
• [18]Vaziri H, Naserhojjati-Roodsari R, Tahsili-Fahadan N, Khojasteh A, Mashhadi-Abbas F, Eslami B, Dehpour AR: Effect of simvastatin administration on periodontitis-associated bone loss in ovariectomized rats. J Periodontol 2007, 78:1561-1567.
• [19]Seto H, Toba Y, Takada Y, Kawakami H, Ohba H, Hama H, Horibe M, Nagata T: Milk basic protein increases alveolar bone formation in rat experimental periodontitis. J Periodontal Res 2007, 42:85-89.
• [20]Seto H, Ohba H, Tokunaga K, Hama H, Horibe M, Nagata T: Topical administration of simvastatin recovers alveolar bone loss in rats. J Periodontal Res 2008, 43:261-267.
• [21]Ma B, Clarke SA, Brooks RA, Rushton N: The effect of simvastatin on bone formation and ceramic resorption in a peri-implant defect model. Acta Biomater 2008, 4:149-155.
• [22]Wheater G, Elshahaly M, Tuck SP, Datta HK, Van Laar JM: The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013, 11:201. BioMed Central Full Text
• [23]Kinane DF, Peterson M, Stathopoulou PG: Environmental and other modifying factors of the periodontal diseases. Periodontol 2000 2006, 40:107-119.
• [24]Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ: The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000, 71:1492-1498.
• [25]Gomes-Filho IS, Passos Jde S, Cruz SS, Vianna MI, Cerqueira Ede M, Oliveira DC, Dos Santos CA, Coelho JM, Sampaio FP, Freitas CO, De Oliveira NF: The association between postmenopausal osteoporosis and periodontal disease. J Periodontol 2007, 78:1731-1740.
• [26]Genco RJ, Borgnakke WS: Risk factors for periodontal disease. Periodontology 2000 2013, 62:59-94.
• [27]Pradeep AR, Rao NS, Bajaj P, Kumari M: Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial. J Periodontol 2013, 84:24-31.
• [28]Lee Y, Schmid MJ, Marx DB, Beatty MW, Cullen DM, Collins ME, Reinhardt RA: The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials 2008, 29:1940-1949.
• [29]Wronski TJ, Dann LM, Scott KS, Cintron M: Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 1989, 45:360-366.
• [30]Horiuchi N, Maeda T: Statins and bone metabolism. Oral Dis 2006, 12:85-101.
• [31]Turner CH: Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97-104.
• [32]Pradeep AR, Thorat MS: Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol 2010, 81:214-222.